ClinicalTrials.gg
CompletedNCT00343460Updated Mar 2, 2026Results posted

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

A Phase 3 interventional study of APF530 and dexamethasone in Nausea and Vomiting and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Heron Therapeutics. Completed at 52 sites in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Heron Therapeutics · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,428
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 290 studies in Nausea with a site in United States — 29 open to participants now, 32 under way, 8 of them phase 3. Nausea · United States.

Enrollment
6th of 260
1,428 · median 86
Started
2006
with 17 others
Phase 3
40 of 290
5 open now
Registered
33rd of 290
by date

Among the 290 studies in Nausea with a site in United States, this one is the 6th largest by enrollment of the 260 interventional ones that give a count, is one of 18 that started in 2006, is one of 40 in phase 3, and was the 33rd registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

29 of the 290 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Nausea studies recruiting now, 22 (42%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Nausea with a site in United States, or all of them as a file.
02

Study summary

This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.

Read the detailed description

OBJECTIVES:

Primary

  • Compare the overall activity and effects of APF530 versus palonosetron hydrochloride in combination with dexamethasone for prophylaxis of acute- or delayed-onset, chemotherapy-induced nausea and vomiting in patients undergoing moderately or highly emetogenic chemotherapy for cancer.

Secondary

  • Evaluate the safety, tolerability, and efficacy of APF530, in terms of prevention of acute- and delayed-onset nausea and vomiting, in these patients.
  • Gather the pharmacokinetics of APF530 in a subset of patients during chemotherapy course 1.
  • Gather ECG data (using 24-hour Holter monitoring) in a subset of patients during chemotherapy course 1.

OUTLINE: This is a randomized, placebo-controlled, double-blind, parallel-group, multicenter study. Patients are stratified according to emetogenicity of scheduled chemotherapy (moderate-risk [level 3 or 4] vs high-risk [level 5]). Patients are randomized to 1 of 3 treatment arms (I, II, and III). Patients who are randomized to receive palonosetron hydrochloride during chemotherapy course 1 (arm I) are then re-randomized to 1 of 2 treatment arms (II and III) after chemotherapy course 1 to receive treatment during chemotherapy courses 2-4.

Patients receive palonosetron hydrochloride or APF530 and/or placebo 30-60 minutes before the start of chemotherapy. Patients receive dexamethasone 30-90 minutes before the start of chemotherapy.

  • Arm I: Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
  • Arm II: Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
  • Arm III: Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.

A subset of patients undergo blood collection periodically during study for analysis of plasma APF530 concentration.

Quality of life is assessed on day 5 after completion of chemotherapy course 1.

After completion of study treatment, patients are followed at approximately 30 days.

03

Conditions studied

  • Nausea and Vomiting
  • Unspecified Adult Solid Tumor, Protocol Specific

Browse trials for

Keywords

  • nausea and vomiting
  • unspecified adult solid tumor, protocol specific
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • or cytologically confirmed malignant disease

    • No head and neck cancer or upper gastrointestinal cancer
  • Scheduled to receive a single day of moderately or highly emetogenic chemotherapy regimen (for ≤ 4 courses)

    • Chemotherapy administration ≤ 4 hours
    • Duration of each course ≤ 28 days
    • Causing nausea and vomiting in 30-100% of patients if untreated according to Hesketh algorithm
  • Must be able to receive standardized doses of dexamethasone for the prevention of emesis during study treatment
  • No greater than mild nausea or any vomiting within 24 hours before beginning study treatment

PATIENT CHARACTERISTICS:

  • performance status 0-2
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No known allergy or to other selective 5-HT3 receptor antagonists or local anesthetics
  • ≤ 500 ms
  • No cardiac abnormality predisposing the patient to arrhythmia
  • No psychological problem that, in the opinion of the investigator, is severe enough to preclude study participation
  • No recent history (i.e., ≤ 1 year) of alcohol or drug abuse
  • No concurrent condition that, in the opinion of the investigator, could affect assessment of study medication or interfere with the nausea/vomiting response (e.g., severe renal or hepatic impairment)

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No radiotherapy 7 days prior to, during, and 5 days after completion of study treatment
  • More than 7 days since prior chemotherapy
  • More than 7 days since prior and no concurrent prohibited medications (e.g., inhibitors or other antiemetic medications)
  • More than 7 days since prior antinausea medications
  • More than 30 days since prior treatment on an trial
  • No other concurrent or dexamethasone at a different dose than study treatment
  • No concurrent use of APF530, palonosetron hydrochloride, or aprepitant as rescue medications
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,428 participants (actual)

Study arms

  • Active comparator
    Arm I

    Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.

    Drug: dexamethasone · Drug: Palonosetron Hydrochloride · Other: placebo

  • Experimental
    Arm II

    Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.

    Drug: APF530 · Drug: dexamethasone · Other: placebo

  • Experimental
    Arm III

    Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.

    Drug: APF530 · Drug: dexamethasone · Other: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1

    Complete Response is defined as no emetic episodes and no use of rescue medications

    Time frame: 0-24 Hours

  2. Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1

    Complete Response is defined as no emetic episodes and no use of rescue medications

    Time frame: 24-120 Hours

Secondary outcomes

  1. Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1

    Complete control is defined as complete response with no more than mild nausea.

    Time frame: 0-120 Hours

  2. Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1

    TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1. TR during delayed-onset phase is defined as Complete Response with no nausea during \>24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.

    Time frame: 0-120 Hours

  3. Number of Emetic Episodes

    Number of Emetic Episodes - days 1-5

    Time frame: Days 1-5

  4. Time to First Treatment Failure

    Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration

    Time frame: 0-120 Hours

  5. First and Overall Use of Rescue Medication

    Time frame: 0-120 Hours

  6. Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)

    Maximum severity of nausea, days 1-5

    Time frame: 0-120 Hours

  7. Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses

    Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles Complete Response is defined as no emetic episodes and no use of rescue medications

    Time frame: 0-120 Hours

  8. Quality of Life and the Impact of Nausea and Vomiting on Day 5

    Functional Living Index

    Time frame: 5 days

  9. Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1

    Subject who were very satisfied on Day 1

    Time frame: 0- 24 Hours

07

Results

Posted Dec 28, 2016

Participant flow

Cycle 1
Participant flow — Cycle 1
MilestoneAPF530 5 mgAPF530 10 mgAloxi 0.25 mg
Started475481472
Completed453459454
Not completed222218
Cycle 2 - 4
Participant flow — Cycle 2 - 4
MilestoneAPF530 5 mgAPF530 10 mgAloxi 0.25 mg
Started5845650
Completed5285150
Not completed56500

Outcome measures

PrimaryProportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1

Complete Response is defined as no emetic episodes and no use of rescue medications

Time frame:
0-24 Hours
Reported as:
Number · participants
Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 Highly
Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1160163156178195192
PrimaryProportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1

Complete Response is defined as no emetic episodes and no use of rescue medications

Time frame:
24-120 Hours
Reported as:
Number · participants
Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 Highly
Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1110125120148164158
SecondaryProportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1

Complete control is defined as complete response with no more than mild nausea.

Time frame:
0-120 Hours
Reported as:
Number · participants
Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 Highly
CC during acute Phase154152147170183184
CC during the delayed-onset phase100115107138150147
CC during the overall risk period9310799127138136
SecondaryProportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1

TR during acute phase is defined as Complete Response with no nausea during 0 to 24 hours following the administration of chemotherapy in Cycle 1. TR during delayed-onset phase is defined as Complete Response with no nausea during \>24 to 120 hours following the administration of chemotherapy in Cycle 1. TR during overall risk period is defined as Complete Response with no nausea during 0 to 120 hours following the administration of chemotherapy in Cycle 1.

Time frame:
0-120 Hours
Reported as:
Number · participants
Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 Highly
TR during acute phase135121113141146158
TR during the delayed-onset phase768973115113122
TR during the overall risk period687965103101117
SecondaryNumber of Emetic Episodes

Number of Emetic Episodes - days 1-5

Time frame:
Days 1-5
Reported as:
Mean · Number of Emetic Episodes
Number of Emetic Episodes
Number of Emetic EpisodesCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 Highly
Number of Emetic Episodes3.4 ± 8.033.1 ± 9.352.1 ± 5.122.3 ± 6.692.4 ± 7.872.5 ± 7.15
SecondaryTime to First Treatment Failure

Proportions of subjects event free at 24, 48, 72, 96, and 120 hours after chemotherapy administration

Time frame:
0-120 Hours
Reported as:
Number · Proportion of subjects event free
Time to First Treatment Failure
Proportion of subjects event freeCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 - Highly
24 Hours0.7380.7630.7550.7810.8110.803
48 Hours0.6360.6590.6350.7060.7230.714
72 Hours0.5330.5640.5670.6490.6850.672
96 Hours0.4850.5500.5340.6180.6680.634
120 Hours0.4850.5400.5290.6000.6470.620
SecondaryFirst and Overall Use of Rescue Medication
Time frame:
0-120 Hours
Reported as:
Number · participants
First and Overall Use of Rescue Medication
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 - Highly
Used Rescue Medication, 0-24 hours423741352325
Used Rescue Medication, 24-120 hours836963604242
Used Rescue Medication, 0-120 hours897672714549
SecondarySeverity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)

Maximum severity of nausea, days 1-5

Time frame:
0-120 Hours
Reported as:
Number · participants
Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 - Highly
None788566105102121
Mild455368536853
Moderate594046483739
Severe303224132819
SecondarySustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses

Sustainability of Overall Complete Response (CR 0-120 hrs) Over Two, Three, and Four Cycles Complete Response is defined as no emetic episodes and no use of rescue medications

Time frame:
0-120 Hours
Reported as:
Number · participants with overall CR
Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses
participants with overall CRCycles 1, 2, 3 and 4 - ModeratelyCycles 1, 2, 3, and 4 - ModeratelyCycles 1, 2, 3 and 4 - HighlyCycles 1, 2, 3, and 4 - Highly
Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses34355652
SecondaryQuality of Life and the Impact of Nausea and Vomiting on Day 5

Functional Living Index

Time frame:
5 days
Reported as:
Number · participants
Quality of Life and the Impact of Nausea and Vomiting on Day 5
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 - Highly
No nausea impact on daily life112127120142142159
No vomiting impact on daily life157162160173182191
SecondaryPatient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1

Subject who were very satisfied on Day 1

Time frame:
0- 24 Hours
Reported as:
Number · participants
Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1
participantsCycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 - Highly
Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 110111398128128135

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cycle 1 APF530 5 mg—42/464 (9.1%)335/464 (72.2%)
Cycle 1 APF530 10 mg—36/468 (7.7%)349/468 (74.6%)
Cycle 1 Aloxi 0.25 mg—27/472 (5.7%)313/472 (66.3%)
Cycles 2-4 APF530 5 mg—61/528 (11.6%)422/528 (79.9%)
Cycle 2-4 APF530 10 mg—73/515 (14.2%)413/515 (80.2%)
Most frequent serious events
Showing 10 of 124
Most frequent serious events
EventCycle 1 APF530 5 mgCycle 1 APF530 10 mgCycle 1 Aloxi 0.25 mgCycles 2-4 APF530 5 mgCycle 2-4 APF530 10 mg
Febrile neutropeniaBlood and lymphatic system disorders2/4647/4683/4725/5288/515
PneumoniaInfections and infestations0/4641/4680/4727/5284/515
NeutropeniaBlood and lymphatic system disorders2/4641/4682/4722/5286/515
DehydrationMetabolism and nutrition disorders1/4642/4682/4724/5286/515
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/4641/4680/4720/5286/515
AnaemiaBlood and lymphatic system disorders2/4640/4682/4726/5282/515
VomitingGastrointestinal disorders1/4644/4681/4721/5283/515
SepsisInfections and infestations1/4641/4682/4724/5281/515
Pleural effusionRespiratory, thoracic and mediastinal disorders3/4640/4680/4724/5280/515
Respiratory failureRespiratory, thoracic and mediastinal disorders2/4643/4681/4724/5281/515
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCycle 1 APF530 5 mgCycle 1 APF530 10 mgCycle 1 Aloxi 0.25 mgCycles 2-4 APF530 5 mgCycle 2-4 APF530 10 mg
Injection site bruisingGeneral disorders78/46493/46841/472124/528153/515
FatigueGeneral disorders62/46462/46852/47280/52894/515
Injection site noduleGeneral disorders22/46450/4683/47257/52890/515
AnaemiaBlood and lymphatic system disorders46/46442/46834/47286/52887/515
AlopeciaSkin and subcutaneous tissue disorders19/46431/46825/47282/52869/515
ConstipationGastrointestinal disorders61/46472/46862/47278/52879/515
NauseaGastrointestinal disorders55/46458/46841/47266/52873/515
DiarrhoeaGastrointestinal disorders47/46444/46839/47251/52869/515
Injection site erythemaGeneral disorders33/46451/46814/47258/52861/515
AstheniaGeneral disorders23/46421/46830/47260/52839/515

Baseline characteristics

Modified Intent-to-Treat Population

Age, Continuous
Age, Continuous(years)Cycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 HighlyTotal
Mean54.8 ± 12.8055.1 ± 12.7957.3 ± 12.3657.6 ± 13.3556.8 ± 13.2058.1 ± 13.7456.62 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)Cycle 1 APF530 5 mg - ModeratelyCycle 1 APF530 10 mg - ModeratelyCycle 1 Aloxi 0.25 mg - ModeratelyCycle 1 APF530 5 mg - HighlyCycle 1 APF530 10 mg - HighlyCycle 1 Aloxi 0.25 HighlyTotal
Female1891771771531521581006
Male253531768880335
08

Study locations

52 sites
  • Anniston Oncology, PC
    Anniston, Alabama 36207, United States
  • Palo Verde Hematology Oncology - Glendale
    Glendale, Arizona 85304, United States
  • Arizona Clinical Research Center, Incorporated
    Tucson, Arizona 85715, United States
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Pacific Cancer Medical Center, Incorporated
    Anaheim, California 92801, United States
  • Southbay Oncology / Hematology Medical Group
    Campbell, California 95008, United States
  • Compassionate Cancer Care Medical Group Incorporated - Corona
    Corona, California 92882, United States
  • Compassionate Cancer Care Medical Group Incorporated - Fountain Valley
    Fountain Valley, California 92708, United States
  • Advanced Research Management Services, Incorporated
    Los Angeles, California 90057, United States
  • Kenmar Research Institute
    Los Angeles, California 90057, United States
  • Medical Oncology Care Associates - Orange
    Orange, California 92868, United States
  • Eastern Connecticut Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
  • Providence Hospital
    Washington D.C., District of Columbia 20017, United States
  • Pasco Pinellas Cancer Center - New Port Richey
    New Port Richey, Florida 34689, United States
  • Innovative Medical Research of South Florida, Incorporated
    North Miami Beach, Florida 33179-4709, United States
  • Columbus Clinic, PC
    Columbus, Georgia 31901, United States
  • Clintell, Incorporated
    Skokie, Illinois 60077, United States
  • Investigative Clinical Research, LLC
    Indianapolis, Indiana 46254, United States
  • Cancer Center of Indiana
    New Albany, Indiana 47150, United States
  • Family Medicine of Vincennes Clinical Trial Center
    Vincennes, Indiana 47591, United States
  • Medical Center Vincennes
    Vincennes, Indiana 47591, United States
  • Kentucky Cancer Clinic - Hazard
    Hazard, Kentucky 41701, United States
  • Kentuckiana Cancer Institute, PLLC
    Louisville, Kentucky 40202, United States
  • Hematology-Medical Oncology Associates at Central Maine Comprehensive Cancer Center
    Lewiston, Maine 04240, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202-2165, United States
  • Center for Cancer and Blood Disorders at Suburban Hospital
    Bethesda, Maryland 20817, United States
  • Center for Clinical Research at Washington County Hospital
    Hagerstown, Maryland 21740, United States
  • Northern Michigan Hospital
    Petoskey, Michigan 49770, United States
  • Regional Cancer Center at Singing River Hospital
    Pascagoula, Mississippi 39581, United States
  • Kansas City Cancer Centers - South
    Kansas City, Missouri 64131, United States
  • Star Hematology & Oncology
    Phillipsburg, New Jersey 08865, United States
  • Veterans Affairs Medical Center - Buffalo
    Buffalo, New York 14215, United States
  • Falck Cancer Center at Arnot Ogden Medical Center
    Elmira, New York 14905, United States
  • Hudson Valley Hematology-Oncology Associates - Poughkeepsie
    Poughkeepsie, New York 12601, United States
  • Comprehensive Cancer Center at Pardee Hospital
    Hendersonville, North Carolina 28791, United States
  • Boice Willis Clinic, PA
    Rocky Mount, North Carolina 27804, United States
  • Eastern North Carolina Medical Group, PLLC
    Rocky Mount, North Carolina 27804, United States
  • McDowell Cancer Center at Akron General Medical Center
    Akron, Ohio 44302, United States
  • Gabrail Cancer Center - Canton Office
    Canton, Ohio 44718, United States
  • Gabrail Cancer Center - Dover Office
    Dover, Ohio 44622, United States
  • MedCentral - Mansfield Hospital
    Mansfield, Ohio 44903, United States
  • Signal Point Hematology Oncology Incorporated
    Middletown, Ohio 45042, United States
  • Cancer Treatment Centers of America at Southwestern Regional Medical Center
    Tulsa, Oklahoma 74133-4564, United States
  • Pottsville Cancer Clinic
    Pottsville, Pennsylvania 17901, United States
  • Charleston Hematology Oncology Associates, PA
    Charleston, South Carolina 29403, United States
  • Julie and Ben Rogers Cancer Institute at Memorial Hermann Baptist Beaumont Hospital
    Beaumont, Texas 77701, United States
  • Texas Cancer Clinic
    San Antonio, Texas 78240, United States
  • Cancer Outreach Associates - Abingdon
    Abingdon, Virginia 24211, United States
  • Virginia Oncology Care, PC
    Richlands, Virginia 24641, United States
  • Western Washington Oncology, Incorporated, PS at Western Washington Cancer Center
    Lacey, Washington 98503, United States
  • MultiCare Regional Cancer Center at Tacoma General Hospital
    Tacoma, Washington 98405, United States
  • Mary Babb Randolph Cancer Center at West Virginia University Hospitals
    Morgantown, West Virginia 26506-9300, United States
09

References and documents

Publications

  • Boccia R, O'Boyle E, Cooper W. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy. BMC Cancer. 2016 Feb 26;16:166. doi: 10.1186/s12885-016-2186-4. PubMed 26921245 ↗
  • Raftopoulos H, Boccia R, Cooper W, O'Boyle E, Gralla RJ. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. Future Oncol. 2015 Sep;11(18):2541-51. doi: 10.2217/fon.15.185. Epub 2015 Aug 20. PubMed 26289588 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Sep 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 8 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2006
First posted
Jun 23, 2006
Start
Jun 2006
Primary completionActual
Sep 2008
CompletionActual
Feb 2009
Results first posted
Dec 28, 2016
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00343460
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Jun 23, 2006
Start date
Jun 2006
Primary completion
Sep 2008
Completion
Feb 2009
Results posted
Dec 28, 2016
Last update
Mar 2, 2026

Study contacts

John Barr, PhD
study chair · Heron Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion